(Total Views: 996)
Posted On: 04/13/2019 10:19:34 PM
Post# of 2145
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
May 7th is Announcement for Isradipine Phase lll Study Results.
Posting elsewhere of old outdate information from February
before the schedule change is being posted.
Now here is the deal, the Steady-PD Results for Phase lll Trials
is on their website stating early May release. In the AAN Meeting
or not the results are coming out.
Isradipine is pure Icing for Elite and did not cost the company for the Study.
If results are good Parkinson's Disease Patient Have a Reason to
Rejoice.
So will ELTP Stockholders.
I did NOT invest for Isradipine but it makes the stock a Triple Play.
1. Generic drugs and Profitable this year.
2. Isradipine Positive Results a WILDCARD.
3. SequestOx turns opioids on their head and becomes the pain drug
of choice, should the FDA get off of its ass and actually do something to HELP the Problem.
Posting elsewhere of old outdate information from February
before the schedule change is being posted.
Now here is the deal, the Steady-PD Results for Phase lll Trials
is on their website stating early May release. In the AAN Meeting
or not the results are coming out.
Isradipine is pure Icing for Elite and did not cost the company for the Study.
If results are good Parkinson's Disease Patient Have a Reason to
Rejoice.
So will ELTP Stockholders.
I did NOT invest for Isradipine but it makes the stock a Triple Play.
1. Generic drugs and Profitable this year.
2. Isradipine Positive Results a WILDCARD.
3. SequestOx turns opioids on their head and becomes the pain drug
of choice, should the FDA get off of its ass and actually do something to HELP the Problem.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)